Intrinsiqq
BioCardia, Inc. logo

BioCardia, Inc.

BCDA

⊜ Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$14M
EPS-$0.09
P/E-9.86
P/FCF-1.83
EV/EBITDA-1.35
FCF Yield–
Div. Yield–
Net Debt/FCF0.5x
BioCardia, Inc. intrinsic value
52-Week Range
$0.77$1.47

Profitability & Returns

Revenue (FY)

$0.00

▼ -100.0% YoY

Net Income (TTM)

-$7M

▼ -3.5% YoY

Op. Margin

–

ROIC

-288.55%

Cash Flow & Balance Sheet

FCF (TTM)

-$8M

▲ +5.7% YoY

Op. Cash Flow (TTM)

-$8M

▲ +5.7% YoY

Net Debt

-$4M

Net Cash Position

Cash & Equiv.

$4M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BCDA

CompareIntrinsic value
PLXProtalix Biotherapeutics Inc.
$2.69+3.07%68
ALLOAllogene Therapeutics Inc.
$1.19+6.25%10
ATRAAtara Biotherapeutics, Inc.
$8.37+2.07%15
ELOXEloxx Pharmaceuticals, Inc.
$12.74-1.39%20
CCCCC4 Therapeutics Inc.
$3.12-2.80%33
AUTLAutolus Therapeutics plc
$1.38-2.83%40
TSHATaysha Gene Therapies Inc.
$4.36+6.60%40
CRDFCardiff Oncology Inc.
$0.87+1.03%36

BioCardia (BCDA) in three numbers

Quality score
20/100
Best check: share count change, -25.4%. Weakest: return on capital, -288.6%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-9.86
Negative: a loss over the last twelve months. Price to free cash flow -1.83.
Financials

Questions about BioCardia

Is BioCardia a high-quality business?

BioCardia scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is share count change at -25.4%, and its weakest is return on capital at -288.6%. The Quality tab shows every check against its target.

Does BioCardia (BCDA) pay a dividend?

No. BioCardia (BCDA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 11 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in BCDA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BCDA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.